SCYNEXIS, Inc. has announced the resumption of patient dosing in the Phase 3 MARIO study of ibrexafungerp, an oral antifungal medication, following the lifting of a clinical hold by the FDA. This ...
In the largest genome study to date, a team led by scientists at the University of Queensland (UQ) has analyzed genetic data of nearly 5.4 million people from 281 genome-wide association studies (GWAS ...
AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ -- Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence. There are now over 100 peer-reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback